Search

Your search keyword '"Joyce S T Lam"' showing total 3 results
Start Over Author "Joyce S T Lam"
3 results on '"Joyce S T Lam"'

1. Demographic and psychometric predictors associated with engagement in risk-associated alternative healthcare behaviours.

Author

Bernie Garrett, Timothy Caulfield, Richard Musoke, Blake Murdoch, Xuyan Tang, and Joyce S T Lam

Subjects
Medicine, Science
Abstract

This paper builds on prior work exploring the use of risk-associated alternative healthcare (RAAH) in Canada. RAAH uptake was surveyed to explore the characteristics of adult RAAH users and the value of established psychometric instruments previously used in alternative healthcare studies in predicting RAAH behaviours: the Control Beliefs Inventory (CBI), the Reward Responsiveness Behavioural Activation System (RBAS) scale, the Positive Attitudes to Science (PAS) scale, the Satisfaction with Orthodox Medicine (SOM) scale, and the brief version of the Susceptibility to Persuasion-II (StP-II-B) scale. Findings suggest RAAH is influenced by gender, age, income, education, employment, chronic illness status, and ethnicity. Engagement in some form of RAAH was common (around 40%) and the most common types of RAAH use reported were physical manipulation and herbal/nutritional supplement use. Other higher-risk AH activities (such as use of toxins and physically invasive procedures) were also reported by about 5% of respondents. The StP-II-B and PAS instruments were predictive of the likelihood of engagement in RAAH behaviours, as illustrated by higher risk tolerance, desire for novelty, positive attitude to advertising and social influence, and positive beliefs about science. The CBI, RBAS, and SOM instruments were not predictive overall. However, the CBI and SOM instruments were predictive of engagement with physical manipulative RAAH activities, while the RBAS was predictive of herbal/nutritional RAAH engagement. These findings can help inform health professionals' understanding of public health-seeking behaviours with respect to risk.

Published
2023
Full Text
View/download PDF

2. The Safety and Feasibility of Mediterranean-Ketogenic Dietary Interventions on Gut Health in Parkinson’s Disease: A Protocol for an Open-label, Randomized, Crossover Design Clinical Trial (KIM Trial)

Author

Shayan Keymanesh, Kira Tosefsky, Joyce S. T. Lam, Avril Metcalfe-Roach, Petra Uzelman, Matthew Sacheli, Wolfram Tetzlaff, Tamara R. Cohen, Cheryl Wellington, B. Brett Finlay, and Silke Appel-Cresswell

Abstract

Background Parkinson’s disease (PD) is the second most common neurodegenerative disorder worldwide, characterized by a constellation of motor and non-motor symptoms. The etiology of PD is not fully understood, however, the early presence of gastrointestinal symptoms and alterations in the gut microbiome suggest a possible intestinal origin. Another pathophysiological feature of PD is an inefficient utilization of glucose by neuronal cells as the main energy source leading to bioenergetic deficits of the brain. Dietary interventions such as the Mediterranean (MeDi) diet and the ketogenic diet (KD) have shown promise in alleviating the gastrointestinal symptoms and bioenergetics deficits of PD, respectively. Nonetheless, classical KDs may unfavorably alter the gut microbiome, e.g., by decreasing short-chain fatty (SCFA) acid levels. Hence, combining the principles of the MeDi and KD may allow us to harness the potential benefits of both these dietary interventions, while maintaining gut health. Methods This study will utilize an open-label, randomized, cross-over design to investigate the safety and feasibility of the Mediterranean-ketogenic diet (MeDi-KD) and MeDi diet supplemented with medium-chain triglycerides (MeDi-MCT) in 50 participants diagnosed with PD. Participants will be randomized to start with either the MeDi-KD or the MeDi-MCT intervention. They will adhere to the respective dietary regimens for 8 weeks followed by an 8-week washout period wherein they will return to their pre-study dietary habits. Following the washout period, the participants will start the other dietary intervention for another 8 weeks. Fecal and blood samples will be collected before and after each intervention to examine the biomarkers associated with gut health. The primary outcome measure of this study will be changes from baseline in fecal SCFA levels, particularly butyrate. Discussion The primary objective of this study is to investigate the safety of two Mediterranean-ketogenic interventions with respect to gut microbiome health in patients with PD. This study will provide preliminary evidence and guidance for subsequent large-scale clinical trials investigating multi-pronged dietary interventions to treat PD. If successful, it will de-risk future studies on ketogenic interventions by providing vital information about the safety, tolerability, adherence, and feasibility of the MeDi-KD and MeDi-MCT. Trial Registration ClinicalTrials.gov Identifier: NCT05469997

Published
2023

Catalog

Books, media, physical & digital resources
See catalog results